Core Viewpoint - vTv Therapeutics (VTVT) has shown a significant price increase of 41.4% over the past four weeks, with a mean price target of $37 indicating a potential upside of 25.2% from the current price of $29.56 [1] Price Targets and Analyst Consensus - The average price target for VTVT ranges from a low of $35.00 to a high of $40.00, with a standard deviation of $2.65, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates an 18.4% increase, while the highest suggests a 35.3% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about VTVT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 9.2% over the past month, with no negative revisions reported [12] - VTVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can often mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Liquidia Corporation (LQDA) has shown a significant price increase of 30.1% over the past four weeks, with a mean price target of $44 indicating a potential upside of 51.2% from the current price of $29.11 [1] Price Targets and Analyst Consensus - The average price target for LQDA includes nine estimates ranging from a low of $16.00 to a high of $67.00, with a standard deviation of $14.33, indicating variability in analyst predictions [2] - The lowest estimate suggests a potential decline of 45%, while the highest indicates a possible upside of 130.2% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about LQDA's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 50.8%, with five estimates moving higher and no negative revisions [12] - LQDA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - ITT has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based solely on changes in a company's earnings picture, which is a critical factor for stock price movements [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. ITT's Earnings Outlook - For the fiscal year ending December 2025, ITT is expected to earn $6.65 per share, consistent with the previous year's reported figure, while the Zacks Consensus Estimate has increased by 2.6% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - ITT's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - Research Solutions Inc. (RSSS) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that upward revisions can lead to increased buying pressure and higher stock prices [4][5]. - Research Solutions is projected to earn $0.14 per share for the fiscal year ending June 2026, with a year-over-year change of zero, but the Zacks Consensus Estimate has increased by 16.7% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions, which positions Research Solutions favorably for potential market-beating returns [9][10].

TTM Technologies (TTMI) closed the last trading session at $58.45, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $76 indicates a 30% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $3.16. While the lowest estimate of $72.00 indicates a 23.2% increase from the current price level, the most optimistic analyst expe ...

Core Viewpoint - Tango Therapeutics, Inc. (TNGX) has seen an 18.2% increase in share price over the past four weeks, closing at $8.9, with a potential upside of 46.1% based on Wall Street analysts' mean price target of $13 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $1.31, indicating variability among analysts [2]. - The lowest price target is $11.00, suggesting a 23.6% increase, while the highest target is $15.00, indicating a potential surge of 68.5% [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about TNGX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 15.1%, with six estimates moving higher and no negative revisions [12]. - TNGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the stock's potential gain, the implied direction of price movement appears to be a useful guide [14].

Core Viewpoint - Enanta Pharmaceuticals (ENTA) shares have increased by 13.7% in the past four weeks, closing at $12.13, with a potential upside of 44.9% based on Wall Street analysts' mean price target of $17.57 [1][4]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates, with a standard deviation of $5.44, indicating variability among analysts [2]. - The lowest estimate is $9.00, suggesting a 25.8% decline from the current price, while the highest estimate is $25.00, indicating a potential surge of 106.1% [2]. - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ENTA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which have increased by 22.4% over the past month [11][12]. - The Zacks Consensus Estimate for the current year reflects this optimism, with no negative revisions reported [12]. - ENTA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While consensus price targets are a common metric for investors, relying solely on them for investment decisions may not be prudent due to historical inaccuracies [3][10]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8].

Group 1 - Sandisk Corporation (SNDK) shares have increased by 17.3% in the past four weeks, closing at $195.96, with a mean price target of $262.54 indicating a potential upside of 34% [1] - The average of 13 short-term price targets ranges from a low of $220.00 to a high of $300.00, with a standard deviation of $23.85, suggesting a potential increase of 12.3% to 53.1% from the current price [2] - Analysts show strong agreement on SNDK's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 75.9% over the past month, with five estimates increasing and no negative revisions [12] - SNDK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide [14]

Group 1 - O-I Glass (OI) closed at $12.7, with a 3.3% gain over the past four weeks, and a mean price target of $16.56 suggests a 30.4% upside potential [1] - The average price targets range from $13.00 to $19.00, with a standard deviation of $2.07, indicating variability among analysts' estimates [2] - Analysts have shown increasing optimism about OI's earnings prospects, with a strong agreement in revising EPS estimates higher, correlating with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 8.3% over the past month, with four estimates going higher and no negative revisions [12] - OI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - ON Holding (ONON) shows potential for significant upside, with a mean price target of $60.68 indicating a 40.1% increase from the current price of $43.3 [1] Price Targets - The average price target consists of 22 estimates, ranging from a low of $30.00 to a high of $85.00, with a standard deviation of $10.3, indicating variability among analysts [2] - The lowest estimate suggests a decline of 30.7%, while the highest indicates a potential upside of 96.3% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual price movements [7][10] Analyst Sentiment - There is strong agreement among analysts regarding ONON's ability to report better earnings, which supports the expectation of an upside [4][11] - Over the past 30 days, five earnings estimates have been revised upward, leading to a Zacks Consensus Estimate increase of 89.2% [12] Zacks Rank - ONON holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion - While the consensus price target may not be a reliable indicator of the extent of potential gains, the direction it implies appears to be a useful guide for further research [14]